SEARCH

SEARCH BY CITATION

References

  • 1
    Severens JL, Laheij RJF, Jansen JBMJ et al. Estimating the costs of lost productivity in dyspepsia. Aliment Pharmacol Ther 1998;12:91923.
  • 2
    Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998;13:17.
  • 3
    Reilly M, Zbrozek A, Dukes E. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:35365.
  • 4
    Reilly M, Tanner A, Meltzer E. Work, classroom and activity impairment instruments: validation studies in allergic rhinitis. Clinical Drug Investigation 1996;11:27888.
  • 5
    Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998;13:66776.
  • 6
    Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992;51 (Suppl. 1):S249.
  • 7
    Drossman DA, Li Z, Andruzzi E et al. US householder survey of functional gastrointestinal disorders. Dig Dis Sci 1993;38:156979.
  • 8
    Agréus L, Svärdsudd K, Nyrén O et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995;109:67180.
  • 9
    Chal KL, Stacey JH, Sacks GE. Effect of ranitidine on symptom relief and quality of life of patients with gastro-oesophageal reflux disease. Br J Clin Pharmacol 1995;49:737.
  • 10
    Rush D, Stelmach J, Young T et al. Clinical effectiveness and quality of life with ranitidine vs. placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract 1995;41:12636.
  • 11
    McDougall N, Collins J, Mcfarland J et al. The effect of treating reflux oesophagitis with omeprazole on quality of life. Eur J Gastroenterol Hepatol 1998;10:45964.
  • 12
    Revicki D, Wood M, Maton P et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998;104:252 8.
  • 13
    Wiklund I, Bardhan KD, Müller-Lissner S et al. Quality of Life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. Ital J Gastroenterol Hepatol 1998;30:1927.
  • 14
    Tew S, Jamieson GG, Pilowsky I et al. The illness behaviour of patients with gastroesophageal reflux disease with and without endoscopic esophagitis. Dis Esophagus 1997;10:915.
  • 15
    Henke CJ, Levin TR, Henning JM et al. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol 2000;95:788 92.
    Direct Link:
  • 16
    Wiklund I, Junghard O, Grace E et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg 1998;164 (Suppl. 583):419.
  • 17
    Sullivan M, Karlsson J, Ware JE. SF-36 Hälsoenkät. Swedish manual and interpretation guide. Gothenburg: Health Care Research Unit, Medical Faculty, Gothenburg University and Sahlgrenska Hospital, 1994.
  • 18
    Talley N, Fullerton S, Junghard O et al. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 2001;96:19982004.
    Direct Link:
  • 19
    Rentz A, Battista C, Trudeau E et al. Symptom and health-related quality of life measures for use in selected gastrointestinal disease studies. Pharmacoeconomics 2001;19:34963.
  • 20
    Ware J. SF-36 Health Survey. Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center, 1993.
  • 21
    Fairclough DL, Cella DF. Functional assessment of cancer therapy (FACT-G): non-response to individual questions. Qual Life Res 1996;5:3219.
  • 22
    Shumaker S, Anderson R, Czajhowski S. Psychological tests and scales. In: Spilker B, ed. Quality of Life Assessments in Clinical Trials. New York: Raven Press, 1990.
  • 23
    Juniper E, Guyatt G, Jaeschke R. How to develop and validate a new health-related quality of life instrument. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials (2nd ed). Philadelphia: Lippincott-Raven, 1996.
  • 24
    Bowling A. Measuring health – a review of quality of life measurement scales. Buckingham: Open University Press, 1998.
  • 25
    Eisen G, Locke III R, Provenzale D. Health-related quality of life: a primer for gastroenterologists. Am J Gastroenterol 1999;94:201721.
    Direct Link:
  • 26
    Brazier J, Deverill M. A checklist for judging preference-based measures of health related quality of life: learning from psychometrics. Health Econ 1999;8:4151.
  • 27
    Junghard O, Lauritsen K, Talley N et al. Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non ulcer dyspepsia. Eur J Surg Supplement 1998;583:106 11.
  • 28
    Wiklund I, Butler-Wheelhouse P. Psychosocial factors and their role in symptomatic gastroesophageal reflux disease and functional dyspepsia. Scand J Gastroenterol Suppl 1996;220:S94100.
  • 29
    Fullerton S, Wiklund I, Talley N et al. Patients with upper gastrointestinal symptoms have a poor quality of life regardless of the presence of esophagitis. Gastroenterology 1999;116:A116.
  • 30
    Stang P, Cady P, Batenhorst A et al. Workplace productivity: a review of the impact of migraine and its treatment. Pharmacoeconomics 2001;19:23144.